135 completed, 86 recruiting, 55 terminated, 49 active not recruiting. 225 Phase 2, 129 Phase 1, 47 Phase 3, 16 Phase 4, 6 Not applicable.
Follow ruxolitinib: new trials by email Literature Review of ruxolitinib trials Research Report on ruxolitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT Ruxolitinib - Transplant-Related Disorder | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 438 | 2027-01-01 | 2026-10-21 |
| Opzelura Experience Study ruxolitinib, ruxolitinib and an Eczema Action Plan - Atopic Dermatitis | Phase 4 | Not yet recruiting | Wake Forest University Health Sciences | 50 | 2026-12-01 | 2026-09-04 |
| Revumenib in Patients With Myelofibrosis Revumenib, Ruxolitinib, FEDRATINIB - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 / Phase 2 | Not yet recruiting | John Mascarenhas | 32 | 2026-12-01 | 2026-07-29 |
| Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts Momelotinib, Ruxolitinib - Myelofibrosis, Myelofibrosis (MF) | Phase 4 | Not yet recruiting | SWOG Cancer Research Network | 268 | 2026-11-01 | 2026-09-17 |
| Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Host Disease (cGvHD) Belumosudil, Ruxolitinib - cGVHD | Phase 2 | Not yet recruiting | Dennis Kim | 53 | 2026-11-01 | 2026-10-02 |
| Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial Ruxolitinib, Pembrolizumab - Carcinoma, Squamous Cell of Head and Neck HNSCC | Phase 2 | Not yet recruiting | University Hospital, Basel, Switzerland | 66 | 2026-11-01 | 2026-10-20 |
| A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025). Bomedemstat, Ruxolitinib, Ropeginterferon alfa-2b - Polycythemia Vera | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 380 | 2026-10-21 | 2026-10-21 |
| Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI Sirolimus, Ruxolitinib, MMF - Acute Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Not yet recruiting | Peking University People's Hospital | 40 | 2026-10-01 | 2026-09-09 |
| Topical Ruxolitinib in Acute Skin GVHD (Graft Versus Host Disease) Ruxolitinib 1.5% cream - Acute Skin Graft Versus Host Disease (GVHD) | Phase 1 | Not yet recruiting | Children's Hospital Medical Center, Cincinnati | 10 | 2026-10-01 | 2026-09-08 |
| Topical Ruxolitinib in the Treatment of Adults With Pyoderma Gangrenosum topical ruxolitinib 1.5% cream - Pyoderma Gangrenosum | Phase 2 | Recruiting | Oregon Health and Science University | 12 | 2026-09-01 | 2026-10-09 |
| A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms DMR-001, Ruxolitinib - Myeloproliferative Neoplasms (MPNs) | Phase 1 | Recruiting | Damora Therapeutics | 250 | 2026-09-01 | 2026-10-27 |
| Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis ropeginterferon alfa- 2b, Ruxolitinib - Myelofibrosis | Phase 1 | Recruiting | University of Utah | 15 | 2026-08-21 | 2026-10-19 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD anti-CD25 rhMAb, Prednisone, Ruxolitinib - cGVHD | Phase 4 | Not yet recruiting | Peking University People's Hospital | 30 | 2026-07-15 | 2026-06-18 |
| Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) Ruxolitinib - Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 16 | 2026-07-15 | 2026-07-28 |
| Ruxolitinib Cream Combined With Corticosteroids for Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study 1.5% Ruxolitinib Phosphate Cream (Opzelura), Corticosteroid Therapy - Non-Segmental Vitiligo (NSV) | Recruiting | ShanShan Li | 300 | 2026-07-02 | 2026-09-08 | |
| Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease Ruxolitinib - Sickle Cell Disease, Hematopoetic Stem Cell Transplant | Phase 1 / Phase 2 | Recruiting | Arkansas Children's Hospital Research Institute | 24 | 2026-06-08 | 2026-06-04 |
| Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental Vitiligo Ruxolitinib 1.5% Cream BID - Vitiligo | Phase 3 | Not yet recruiting | The Children's Hospital of Zhejiang University School of Medicine | 20 | 2026-06-01 | 2026-05-19 |
| Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer Biopsy, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-06-01 | 2026-05-05 |
| A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) Pelabresib, Ruxolitinib, Placebo - Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 460 | 2026-05-27 | 2026-10-26 |
Showing 20 of 385. Sign in to see all of them.
Primary Myelofibrosis (102) · Myeloproliferative Disorders (35) · Polycythemia Vera (29) · Graft vs Host Disease (26) · Leukemia, Myeloid, Acute (25) · COVID-19 (18) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (18) · Leukemia (17) · Myelodysplastic Syndromes (17) · Thrombocythemia, Essential (16) · Dermatitis, Atopic (12) · Bronchiolitis Obliterans Syndrome (11) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (10) · Recurrence (10) · Breast Neoplasms (9)
Incyte Corporation (60) · Novartis Pharmaceuticals (35) · M.D. Anderson Cancer Center (21) · Memorial Sloan Kettering Cancer Center (9) · AbbVie (6) · Fred Hutchinson Cancer Center (6) · Institute of Hematology & Blood Diseases Hospital, China (6) · St. Petersburg State Pavlov Medical University (6) · Chinese PLA General Hospital (5) · City of Hope Medical Center (5) · H. Lee Moffitt Cancer Center and Research Institute (5) · John Mascarenhas (5) · Mayo Clinic (5) · OHSU Knight Cancer Institute (5) · Washington University School of Medicine (5)
United States (244) · France (63) · Italy (63) · Germany (61) · Canada (56) · Spain (55) · United Kingdom (50) · China (44) · Belgium (36) · Australia (35) · South Korea (34) · Israel (31) · Poland (31) · Japan (28) · Netherlands (24)
John Mascarenhas, MD (5) · Albert Assad, MD (4) · Daihong Liu (4) · Haris Ali (3) · Pooja Khandelwal, MD (3) · Rachel B. Salit (3) · Srdan Verstovsek, MD (3) · Srdan Verstovsek, MD, PhD (3) · William Williams, MD (3) · Aaron R Mangold (2) · Alison Moskowitz, MD (2)
PMID 29316837, PMID 38485149, PMID 23911705, PMID 26069290, PMID 28962635, PMID 29396713, PMID 29508247, PMID 33067379, PMID 35175355, PMID 40472328, PMID 41890273, PMID 42154791, PMID 42180389, PMID 42842696, PMID 17709602, PMID 20843246, PMID 22281165, PMID 22375970, PMID 22375971, PMID 22422826, PMID 22718840, PMID 23423753, PMID 24038026, PMID 24056820, PMID 24174625, PMID 24283202, PMID 24327518, PMID 25180155, PMID 25441108, PMID 25616577, PMID 25629741, PMID 25682576, PMID 25999444, PMID 26088933, PMID 26228487, PMID 26228813, PMID 26351344, PMID 26380150, PMID 26819050, PMID 27102499, PMID 27247324, PMID 27424289, PMID 27579615, PMID 27699253, PMID 27801315, PMID 27892949, PMID 27916398, PMID 28089238, PMID 28193568, PMID 28228106
2023 (14), 2019 (4), 2025 (4), 2014 (3), 2017 (3), 2018 (3), P01CA108671 (3), P30CA033572 (3), 2015 (2), 2016 (2), P30CA016672 (2), P50CA186781 (2), R01CA262613 (2), 2008 (1), 2009 (1)